rs20541 — IL13 R130Q

IL-13 R130Q — The Th2 Cytokine Amplifier at the Heart of Atopic Disease

Interleukin-13 is the central cytokine of type 2 immune responses¹¹ type 2 immune responses
Th2 immunity orchestrates anti-parasitic defense and allergic inflammation; it is mediated by T-helper 2 cells, ILC2 innate lymphoid cells, and mast cells, and is characterized by IL-4, IL-5, IL-13, and IgE production. While IL-4 drives central T-cell differentiation, IL-13 executes the peripheral tissue damage that defines atopic dermatitis: it remodels the skin barrier, recruits eosinophils, stimulates IgE production, and alters the skin microbiome. The rs20541 variant lies in the IL13 coding sequence and changes a single amino acid at position 130 of the mature peptide. The minor A allele (Q130, present in ~20% of European chromosomes) produces an IL-13 protein with subtly altered receptor engagement, and this change has measurable consequences for IgE levels and atopic disease risk across multiple populations.

The Mechanism

rs20541 is a missense variant that substitutes glutamine (Q) for arginine (R)²² glutamine (Q) for arginine (R)
The substitution is at position 130 of the mature IL-13 peptide (position 144 in the full precursor including the 18-residue signal peptide); rs20541-A encodes Gln, rs20541-G encodes Arg at a site in helix D of the IL-13 four-helix bundle. IL-13 signals through a two-step receptor assembly: low-affinity binding to IL-13Rα1, then recruitment of IL-4Rα to form the high-affinity Type II receptor complex that drives STAT6 phosphorylation. The Q130 (A allele) variant alters the surface charge near the IL-13Rα1 binding interface; evidence from gene association studies indicates it produces functionally enhanced IL-13 signaling, as reflected in measurably elevated serum IgE across multiple ancestry groups. IL-13 acting through Type II receptors in keratinocytes suppresses the expression of filaggrin and other barrier proteins, directly connecting elevated IL-13 tone to the skin barrier defects central to atopic dermatitis. In the skin of AD patients, IL-13 is the dominant Th2 cytokine in the chronic phase, making the genetic amplification of its activity clinically consequential.

The Evidence

The IL13/5q31 locus is one of the most consistently replicated in allergy genetics, and rs20541 sits within it as the primary coding variant. A 2023 European and multi-ancestry GWAS meta-analysis³³ 2023 European and multi-ancestry GWAS meta-analysis
Budu-Aggrey et al., Nature Communications; European discovery: ~21,000 AD cases and ~95,000 controls; 23andMe European replication: 2.9 million individuals identified the 5q31 locus at P<10⁻³⁶ for atopic dermatitis, with the G allele (Arg-130) appearing as the protective effect allele (OR≈0.91). The effect is additive: each copy of the A allele (Gln-130) incrementally increases risk. Fine-mapping in Japanese cohorts (pilot n=939, replication n=2,377)⁴⁴ Japanese cohorts (pilot n=939, replication n=2,377)
Hirota et al. 2020, JACI confirmed rs20541 significantly associated with total serum IgE (a biological measure of Th2 activation), while a separate 3'-UTR variant (rs1295685) tags independent regulatory effects on IL13 expression.

In a Singapore cohort of 1,322 ethnic Chinese⁵⁵ 1,322 ethnic Chinese
Andiappan et al. 2013, Gene, rs20541 was significantly associated with allergic rhinitis, with the homozygous AA genotype carrying OR=1.57 for allergic rhinitis compared to GG. Korean case-control data (631 AD patients, 458 controls)⁶⁶ (631 AD patients, 458 controls)
Jo et al. 2011 found rs20541 particularly enriched in the allergic-type AD subgroup (elevated serum IgE). A Taiwanese nursing study⁷⁷ Taiwanese nursing study
OR=3.38 for AA under recessive model; non-atopic hand eczema found the AA genotype carried OR=3.38 for non-atopic hand eczema under a recessive model. The COCOA birth cohort (1,637 Korean children)⁸⁸ (1,637 Korean children)
Ha et al. 2014 and Lee et al. 2021 showed that GA/AA genotype combined with early antibiotic exposure raised the risk of early-persistent atopic dermatitis to aOR=4.73 — a striking gene-environment interaction indicating that the IL-13 genotype is especially consequential when the early-life microbiome is disrupted.

A 2024 Mendelian randomization study used rs20541 as a genetic instrument to mimic IL-13 inhibition in 563,946 individuals⁹⁹ IL-13 inhibition in 563,946 individuals
Rukin et al. 2024. Genetically proxied IL-13 inhibition was associated with markedly elevated risk of psoriatic arthritis (OR 37.39) and psoriasis (OR 20.08) — confirming that the same cytokine that protects against psoriasis drives atopy. This finding supports the real-world observation that dupilumab (an IL-4Rα blocker suppressing both IL-4 and IL-13) occasionally triggers psoriasiform skin reactions in a subset of atopic dermatitis patients.

Practical Implications

Carriers of the AA genotype have the highest constitutive IL-13 signaling of the three genotypes. This translates to measurably higher baseline serum IgE, a greater tendency to mount Th2 responses to environmental allergens, and elevated lifetime risk for atopic dermatitis, allergic rhinitis, and eczema. Two biologics directly target the IL-13 pathway: tralokinumab¹⁰¹⁰ tralokinumab
Anti-IL-13 monoclonal antibody approved for moderate-severe atopic dermatitis; specifically neutralizes IL-13 protein, making it the most direct pharmacological intervention for carriers of the Q130 IL-13 variant (Adbry, anti-IL-13 monoclonal antibody) and dupilumab (Dupixent, anti-IL-4Rα, blocking both IL-4 and IL-13 signaling). Carriers of the A allele — particularly AA homozygotes — are biologically the ideal candidates for IL-13-targeted therapy when their atopic disease is inadequately controlled by conventional treatment. Baseline biomarker measurement (serum IgE, periostin, DPP-4) helps confirm elevated IL-13 pathway activity before initiating biologic therapy.

Interactions

rs20541 interacts with the filaggrin (FLG) null allele ecosystem: IL-13 directly suppresses filaggrin expression through STAT6 signaling, so carriers of both IL-13 Q130 (A allele) and FLG loss-of-function variants face compounding barrier defects — both structural (absent filaggrin) and inflammatory (elevated IL-13 suppressing residual barrier). A compound action should be considered for rs20541-AA combined with FLG null variants (rs61816761, rs558269137, rs372628716).

The rs1801275 variant (IL-4Rα R576Q) alters the IL-4Rα signal transduction unit shared by both IL-4 and IL-13 receptors. Individuals carrying both rs20541-A (enhanced IL-13 ligand) and rs1801275 risk allele (altered receptor) may face additive Th2 dysregulation — documented mechanistic interactions exist for both nodes of the same receptor complex. This interaction is relevant to dupilumab pharmacogenomics, as dupilumab targets IL-4Rα directly.